TOP TEN perturbations for 38502_at (Homo sapiens)

Organism: Homo sapiens
Gene: 38502_at
Selected probe(set): 214136_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38502_at (214136_at) across 6674 perturbations tested by GENEVESTIGATOR:

AsPC-1 / BxPC-3

Relative Expression (log2-ratio):3.0106306
Number of Samples:3 / 3
Experimental AsPC-1
Human xenograft derived metastatic cancer cell line derived from mouse xenografts initiated with metastatic cells from the ascites derived from a 62 years old female Caucasian patient with pancreatic adenocarcinoma. Synonyms:AsPc-1; Aspc-1; ASPC-1; As-PC1; ASPC1; AsPC1; Aspc1; AsPc1 Cellosaurus code:
Control BxPC-3
Human pancreatic adenocarcinoma cell line derived from a 61 years old female patient. Synonyms:BxPc-3; BXPC-3; Bx-PC3; BXPC3; BxPC3; BxPc3 Cellosaurus code:

TC-71 / TC-32

Relative Expression (log2-ratio):2.6838474
Number of Samples:6 / 6
Experimental TC-71
Human primary cancer cell line derived from the humerus of a patient with Ewing sarcoma. Synonyms:TC71; GM11654 Cellosaurus code:
Control TC-32
Human primary cancer cell line derived from the unspecified origin of a patient with Ewing’s sarcoma. Synonyms:TC32 Cellosaurus code:

CAR T cell study 4 (GFP; post-infusion) / CAR T cell study 4 (GFP; pre-infusion)

Relative Expression (log2-ratio):-1.9002876
Number of Samples:3 / 3
Experimental CAR T cell study 4 (GFP; post-infusion)
CD8+ T cells transduced with GFP and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding GFP as a control. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing GFP (control group). Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples).
Control CAR T cell study 4 (GFP; pre-infusion)
Primary human CD8+ T cells stimulated ex vivo and transduced to express GFP. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding GFP as a control. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples).

torkinib (PP242) study 1 (1uM; 12h; polysome-associated RNA) / metformin study 7 (10mM; 12h; polysome-associated RNA)

Relative Expression (log2-ratio):1.7840433
Number of Samples:4 / 4
Experimental torkinib (PP242) study 1 (1uM; 12h; polysome-associated RNA)
MCF7 cells were treated with IC50 concentration of PP242 (1 uM) for 12 hours. RNA fractions associated with >3 ribosomes were pooled (polysome-associated mRNA) and analyzed. ATC code:---
Control metformin study 7 (10mM; 12h; polysome-associated RNA)
MCF7 cells were treated with IC50 concentration of metformin (10mM) for 12 hours. RNA fractions associated with >3 ribosomes were pooled (polysome-associated mRNA) and analyzed. metformin ATC code:

PMA study 8 (0.0001 uM; Hep-G2) / vehicle (DMSO) treated Hep-G2 cell sample

Relative Expression (log2-ratio):-1.7554293
Number of Samples:3 / 9
Experimental PMA study 8 (0.0001 uM; Hep-G2)
Hep-G2 cells exposed to 0.0001 uM PMA (dissolved in 0.5% v/v DMSO) for 72 hours. Synonyms: phorbol-12-myristat-13-acetate (PMA), tetradecanoylphorbol-acetate (TPA), tetradecanoyl phorbol acetate, 12-O-tetradecanoylphorbol-13-acetate. Cells were exposed to the chemical when 80% confluence was reached. Cells were treated with the IC10 determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (number of replicates, n = 3). ATC code:---
Control vehicle (DMSO) treated Hep-G2 cell sample
Hep-G2 cells treated with vehicle (DMSO 0.5% v/v) for 72 hours. Cells were exposed to the vehicle when 80% confluence was reached.

hepatocyte (ESC) / HepaRG

Relative Expression (log2-ratio):-1.7533188
Number of Samples:8 / 12
Experimental hepatocyte (ESC)
Hepatocyte-like cells differentiated from embryonic stem cells (ESC)
Control HepaRG
Immortalized cancer cell line derived from female patient with hepatocellular carcinoma. Cells can be induced to differentiate into hepatocyte-like cells by exposure to DMSO. Synonyms:Hepa-RG Cellosaurus code:

male infertility study 1 (juvenile; Ad+) / normal testicular lobules tissue (mJS10)

Relative Expression (log2-ratio):-1.6758137
Number of Samples:5 / 8
Experimental male infertility study 1 (juvenile; Ad+)
Human testicular lobules biopsy samples isolated from prepubescent patients with undescended testes. Testes of these children contained typical level of A-dark (Ad+) spermatogonial cells.
Control normal testicular lobules tissue (mJS10)
Biopsies of human testicular lobules isolated from fertile vasectomized adult men with normal spermatogenesis. Histological analysis classified samples as mJS10 (modified Johnsen score 10).

glioma study 16 (LN-229) / normal astrocyte sample

Relative Expression (log2-ratio):1.6601067
Number of Samples:2 / 3
Experimental glioma study 16 (LN-229)
Human glioma cell line LN229 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2.
Control normal astrocyte sample
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal B-cell sample

Relative Expression (log2-ratio):1.635232
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal B-cell sample
MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

VTX-2337 study 1 / 3M-055 study 1

Relative Expression (log2-ratio):-1.5888596
Number of Samples:3 / 3
Experimental VTX-2337 study 1
Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM VTX-2337 drug, which represents a TLR8 (Toll-like receptor 8) agonist with potential immunostimulating and antineoplastic activities.
Control 3M-055 study 1
Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM 3M-055 drug, which represents a TLR7 (Toll-like receptor 7) agonist.